tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ANAB Stock Latest News

AnaptysBio’s Promising Pipeline and Financial Stability Justify Buy Rating
RatingsAnaptysBio’s Promising Pipeline and Financial Stability Justify Buy Rating
1h ago
ANAB
AnaptysBio price target raised to $45 from $40 at Wedbush
PremiumThe Fly
AnaptysBio price target raised to $45 from $40 at Wedbush
22h ago
ANAB
Promising Clinical Trial Results and Strategic Growth Potential Drive Buy Rating for AnaptysBio
PremiumRatings
Promising Clinical Trial Results and Strategic Growth Potential Drive Buy Rating for AnaptysBio
1d ago
ANAB
AnaptysBio Reports Q2 2025 Financial Results and Updates
PremiumCompany Announcements
AnaptysBio Reports Q2 2025 Financial Results and Updates
1d ago
ANAB
AnaptysBio: Promising Pipeline and Strategic Developments Justify Buy Rating
PremiumRatings
AnaptysBio: Promising Pipeline and Strategic Developments Justify Buy Rating
1d ago
ANAB
AnaptysBio reports Q2 EPS ($1.34), consensus ($1.58)
PremiumThe FlyAnaptysBio reports Q2 EPS ($1.34), consensus ($1.58)
2d ago
ANAB
AnaptysBio Faces Critical Risk: Potential Impact on Operations and Investor Confidence
Premium
Company Announcements
AnaptysBio Faces Critical Risk: Potential Impact on Operations and Investor Confidence
7d ago
ANAB
AnaptysBio Holds 2025 Annual Stockholders Meeting
Premium
Company Announcements
AnaptysBio Holds 2025 Annual Stockholders Meeting
2M ago
8K
ANAB
AnaptysBio shares are undervalued, says JPMorgan
PremiumThe Fly
AnaptysBio shares are undervalued, says JPMorgan
2M ago
ANAB
AnaptysBio participates in a conference call with JPMorgan
PremiumThe Fly
AnaptysBio participates in a conference call with JPMorgan
2M ago
ANAB
Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for AnaptysBio’s Rosnilimab
PremiumRatings
Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for AnaptysBio’s Rosnilimab
2M ago
ANAB
AnaptysBio’s rosnilimab demonstrates safety in Phase 2b trial, says Leerink
PremiumThe Fly
AnaptysBio’s rosnilimab demonstrates safety in Phase 2b trial, says Leerink
2M ago
JNJ
ANAB
AnaptysBio’s Promising Phase 2 Trial Results and Strategic Plans Lead to Stock Upgrade
PremiumRatingsAnaptysBio’s Promising Phase 2 Trial Results and Strategic Plans Lead to Stock Upgrade
2M ago
ANAB
AnaptysBio upgraded to Buy from Neutral at H.C. Wainwright
Premium
The Fly
AnaptysBio upgraded to Buy from Neutral at H.C. Wainwright
2M ago
ANAB
Promising Potential of AnaptysBio’s Rosnilimab: A Buy Rating Backed by Strong Phase 2b Trial Results and Strategic Outlook
Premium
Ratings
Promising Potential of AnaptysBio’s Rosnilimab: A Buy Rating Backed by Strong Phase 2b Trial Results and Strategic Outlook
2M ago
ANAB
Closing Bell Movers: Guidewire up 11% after Q3 beat, guidance raise
PremiumThe Fly
Closing Bell Movers: Guidewire up 11% after Q3 beat, guidance raise
2M ago
HPE
HQY
AnaptysBio Reports Positive Phase 2b Trial Results
PremiumCompany Announcements
AnaptysBio Reports Positive Phase 2b Trial Results
2M ago
8K
ANAB
AnaptysBio announces investigational rosnilimab data
PremiumThe Fly
AnaptysBio announces investigational rosnilimab data
2M ago
ANAB
AnaptysBio price target raised to $90 from $54 at Guggenheim
PremiumThe Fly
AnaptysBio price target raised to $90 from $54 at Guggenheim
2M ago
GSK
ANAB
AnaptysBio Reports Strong Q1 2025 Results and Progress
PremiumCompany AnnouncementsAnaptysBio Reports Strong Q1 2025 Results and Progress
3M ago
ANAB
AnaptysBio price target raised to $54 from $52 at Guggenheim
Premium
The Fly
AnaptysBio price target raised to $54 from $52 at Guggenheim
3M ago
ANAB
Hold Rating for AnaptysBio Amid Uncertainties in Clinical Trial Data and Market Position
Premium
Ratings
Hold Rating for AnaptysBio Amid Uncertainties in Clinical Trial Data and Market Position
3M ago
ANAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >